title: Rifampin-induced hypothyroidism.
abstract: Three euthyroid patients with Hashimoto's thyroiditis developed hypothyroidism after the administration of rifampin. We studied 67 patients with tuberculosis. All of them were treated with rifampin. Of the 67 patients, 42 had negative tests for anti-thyroid antibodies (ATA) and 25 had positive tests for ATA. The diagnosis of Hashimoto's thyroiditis was made on the basis of positive tests for ATA. After the administration of rifampin, TSH levels were not significantly altered in all of the former 42 ATA-negative patients and in 22 of the latter 25 ATA-positives, but TSH levels increased in the other three (Patients 1, 2 and 3) of the latter 25 ATA-positives. Three euthyroid Hashimoto's patients (Patients 1, 2 and 3) developed hypothyroidism after the administration of rifampin. This rifampin-induced hypothyroidism resolved in each, once rifampin was discontinued. A) Patient 1: a 62-yr-old man with lymphoma had pulmonary tuberculosis. After the administration of rifampin, serum TSH increased to 170 mU/l; B) Patient 2: a peritoneal-biopsy specimen containing Langhans' giant cells led to a diagnosis of tuberculous peritonitis in a 66-yr-old woman with ascites. After the administration of rifampin, TSH increased to 12.4 mU/l; C) Patient 3: a 56-yr-old woman with a liver abscess and lymphadenopathy underwent lymph-node biopsy that showed Mycobacterium tuberculosis with caseating granulomas. After the administration of rifampin, TSH increased to 21.3 mU/l. After its administration, Patients 1, 2 and 3 developed hypothyroidism, and received T4. When rifampin was discontinued, the hypothyroidism resolved. After the course of rifampin-therapy had been completed, T4 was discontinued. At-risk patients who receive rifampin may become hypothyroid.
authors.affiliation: Department of Endocrinology and Metabolism, Second Department of Internal Medicine, University of the Ryukyus School of Medicine, Nishihara, Okinawa 902-0215, Japan. takasun@med.u-ryukyu.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Takasu
authors.forename: Y
authors.initials: Y
authors.lastname: Kinjou
authors.forename: T
authors.initials: T
authors.lastname: Kouki
authors.forename: M
authors.initials: M
authors.lastname: Takara
authors.forename: Y
authors.initials: Y
authors.lastname: Ohshiro
authors.forename: I
authors.initials: I
authors.lastname: Komiya
mesh_terms: D000368:Aged; D000904:Antibiotics, Antitubercular / Q000009:adverse effects*; D005260:Female; D050031:Hashimoto Disease / Q000150:complications; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced* / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000150:complications / Q000188:drug therapy; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage; D014376:Tuberculosis / Q000188:drug therapy
chemical_list: D000904:Antibiotics, Antitubercular; D013972:Thyrotropin; D013974:Thyroxine; D012293:Rifampin